We can’t afford to gamble with health sector

Africa's healthcare infrastructure stands at a critical juncture. Across the continent, governance failures are creating cascading failures in hospital operations, pharmaceutical supply chains, and patient outcomes—with profound implications for foreign investors betting on healthcare expansion.

The challenge is systemic. Many African health ministries operate without adequate financial controls, transparent procurement processes, or accountability mechanisms. When governance collapses, the consequences ripple through entire sectors. A single procurement scandal in a national health service doesn't just waste millions in public funds—it erodes trust in private partnerships, delays infrastructure investments, and creates regulatory uncertainty that deters institutional capital.

For European entrepreneurs operating health-adjacent businesses in Africa—medical device distributors, diagnostic labs, pharmaceutical supply chains, hospital management firms—governance failures in public health systems represent both a cautionary tale and a strategic inflection point.

**The Scale of the Problem**

Sub-Saharan Africa accounts for approximately 24% of the global disease burden while commanding only 3% of global health expenditure. This gap typically gets filled by either international aid (often with strings attached) or private investment. However, when public health systems fail due to corruption or mismanagement, the political backlash often targets *all* healthcare actors, including private operators. Governments respond by imposing price controls, demanding equity stakes, or threatening to revoke licenses—actions that directly threaten investor returns.

Recent cases illustrate the pattern: procurement scandals in East African health ministries have delayed hospital upgrades by 18-24 months, disrupted medical equipment supply contracts, and triggered regulatory reviews that created multi-year compliance bottlenecks for private providers.

**Market Implications for European Investors**

European healthcare investors typically approach Africa through three pathways: (1) direct hospital or clinic ownership, (2) medical supply/distribution partnerships, or (3) diagnostic and laboratory services. Each faces governance risk differently.

Direct hospital operators are most vulnerable. When public health budgets collapse due to embezzlement or misallocation, referral patterns shift unpredictably, and private facilities lose patient volume. Additionally, governments may suddenly impose price caps or demand free services as political cover for public system failures.

Supply-side investors face different risks: when procurement is non-transparent, relationships become critical. A change in health ministry leadership can instantly eliminate a distributor's market access, regardless of product quality. This favors large multinational firms over smaller European specialists.

Diagnostic and lab services occupy a middle ground—they're less politically sensitive—but remain dependent on hospital partnerships that may themselves become unstable.

**Strategic Recalibration**

Smart European investors are pivoting toward models that reduce governance exposure: (1) B2B diagnostics serving private clinics rather than public facilities; (2) specialized equipment for niche markets (oncology, orthopedics) where private demand is stable; (3) technical training and capacity-building contracts that generate recurring revenue independent of budget cycles.

The broader lesson: Africa's healthcare opportunity remains real—demographics and rising incomes support long-term growth. But entry strategies must account for governance volatility. Projects relying on public sector stability or government procurement are increasingly risky. Those anchored to private demand and B2B relationships are more durable.

#